Overall survival (OS) of patients based on therapy related status, AML vs. MDS, bone marrow blast percentage strata, and TP53 status in all patients and in the MDS and AML subsets. (A) OS of all patients based on therapy-related (median, 10.2 months) vs de novo status (median, 12.2 months), P = .08. (B) OS of all patients based on MDS (median OS, 13.0 months) vs AML (median, 9.4 months, P = .52). (C) OS of all patients based on BM blasts 0% to 4% (median, 14 months) vs 5% to 9% blasts (median, 15.5 months) vs 10% to 19% blasts (median, 10.5 months) vs >20% blasts (median, 9.5 months) (P = .52). (D) OS of all patients based on TP53 mutation status; no mutation (median, 33.9 months) vs TP53 monoallelic (median, 12.5 months) vs TP53 multihit (median, 9.4 months), P < .0001. For TP53 monoallelic vs multihit, P = .05. (E) OS of MDS patients based on TP53 mutation status; no mutation (median, 36.5 months) vs TP53 monoallelic (median, 15.4 months) vs TP53 multihit (median, 10.2 months), P < .0001. For TP53 monoallelic vs multihit, P = .02. (F) OS of AML patients based on TP53 mutation status; no mutation (median, 23.2 months) vs TP53 monoallelic (median, 5.2 months) vs TP53 multihit (median, 9.0 months), P = .003. For TP53 monoallelic vs multihit, P = .68.